A study for serum Irisin level and its influencing factors in patients with fracture

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900021723

Enrollment

Unknown

Registered

1990-01-01

Start date

2019-03-11

Completion date

Unknown

Last updated

2019-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinical fractures

Interventions

Case series:No

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Clinical fracture cases aged over 18 years.

Exclusion criteria

Exclusion criteria: (1) Multiple injuries; (2) Malignant tumor, sarcopenia, liver insufficiency and renal insufficiency (creatinine >1.5 mg/dl), metabolic abnormalities (not included diabetes), severe edema and autoimmune diseases; (3) Without informed consents, lost blood samples, or current medications used that influence serum irisin levels; (4) Pathological fracture.

Design outcomes

Primary

Measure	Time frame
Irisin;	—

Secondary

Measure	Time frame
Serum glucose;Serum albumin;Inflammation marker;	—

Countries

China

Contacts

Public ContactYin Ke

357520637@qq.com+86 18973405240

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026